Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.
about
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast CancerRelevance of tumor-infiltrating lymphocytes in breast cancerCurrent Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast CancerTumor microenvironment and the pathologist: looking at what we just seeNovel therapeutic strategies for patients with triple-negative breast cancerMicroenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration AnalysisStrategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity.Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancerEmerging therapies for breast cancerThe innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer.Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patientsAn ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer.Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant SettingDifferential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer.Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.Advances in systemic therapy for metastatic breast cancer: future perspectives.Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score.Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.Spatial Heterogeneity in the Tumor Microenvironment.Advancing Immunotherapy in Metastatic Breast Cancer.Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer.Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy.RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tuTumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer.Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
P2860
Q26745446-601B3C43-F730-4D03-8610-5C9A76B46145Q26795598-DFFDA5E1-C1F0-4237-A7D9-50BA39226C95Q26798074-3B304A30-76FD-46DF-95A7-D71E6FA78C8FQ26866052-41C697E2-5F10-4007-96D6-FCB237C5B12EQ28067436-8E433AAE-6722-4AA8-893D-A8A631401211Q28604224-E03D7868-368B-47EA-8CF3-E46C39C7AB55Q30857631-8959F44F-3FD9-418B-B32D-6E12B08FFC80Q33554629-3BAE2713-AB4D-48EB-A1D5-033D9EDBF862Q33576409-740DFAB0-1D1A-4FCF-8F38-D8A703E243F5Q33617949-CEE44817-56E7-47AD-932A-1A3A439F4149Q33660069-7AF83278-45D6-42C6-B71C-326AFE3D4274Q33769821-EB99384D-D595-4369-88A8-DBA7C3982114Q34454922-09788565-2819-4CF2-8A6F-97DBC4918802Q34690824-4D44278A-4A73-4D8A-A3F2-3A03BA2BB898Q35009369-7DEBCDB0-7D27-4903-A2EE-CC9DBA51F6D6Q35085679-18429256-56F1-4D7E-A4B8-90B0868B383AQ36085118-6BFB18A7-D349-4AE5-8537-F2D926E696AAQ36228539-E6FB870F-49A3-4034-83DC-22155BBEE301Q36673469-A2FC88B1-7BD0-47B5-B7FD-475A057F86B6Q37138871-3DA07151-AEDE-4129-AB37-04144B7AA23DQ37536862-69752B53-76C4-4593-9482-2969F5E2A8D6Q38639746-544D5A69-0948-474C-88F6-6BEAA5FBC246Q38681576-4B205903-FF76-4530-BB8F-C8C34D11254DQ38798752-E5FEB0E4-D36E-47BD-8CF5-9A4CD382B3B2Q38823649-1915EBEE-A2F8-4EE2-92D0-9C8826D09740Q38915791-2B4A5B2D-6B5C-43E5-ACED-9AC5196C7A68Q39324161-87406B43-FEBA-48FF-8687-98482FFA4EABQ39685538-2B50A1D4-9D15-496F-A704-A93A50079FE1Q40386096-A098CD1C-EB18-4495-AADB-07CC6CA454F8Q41189272-C5699D82-19C9-4028-B52F-C2610C30CB0EQ41346864-67391866-FCE7-48FF-A5BD-A605EDEC27A3Q41719270-0617ACCF-7FCC-48D1-B643-18C9B4D475B3Q42144454-88EEF171-A53E-4118-B7BC-620C79144409Q44857989-B624A3AA-FEA0-4E13-BC19-DE6E30EC3743Q47763725-C5FDB31A-CFF1-42B7-AA0E-D3605123A775Q48121626-06D97AA3-EEB8-490C-935B-F313C5461501Q48219547-9F1B4819-095C-47DD-89FD-C6C29CBC4AE1Q48850918-670A003C-A9A5-415F-B67D-0BBEE4DF9C4FQ50066888-B9DCBDE9-A56B-4664-B303-610F883CCC30Q50862543-7510A47C-2231-4C3D-8DED-B8FCC2EF58F6
P2860
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Prospective validation of immu ...... neoadjuvant GeparQuinto trial.
@ast
Prospective validation of immu ...... neoadjuvant GeparQuinto trial.
@en
type
label
Prospective validation of immu ...... neoadjuvant GeparQuinto trial.
@ast
Prospective validation of immu ...... neoadjuvant GeparQuinto trial.
@en
prefLabel
Prospective validation of immu ...... neoadjuvant GeparQuinto trial.
@ast
Prospective validation of immu ...... neoadjuvant GeparQuinto trial.
@en
P2093
P2860
P50
P1433
P1476
Prospective validation of immu ...... neoadjuvant GeparQuinto trial.
@en
P2093
Frank Holms
Friedrich Overkamp
Georg Kunz
Hans-Ullrich Ulmer
Iris Schrader
Jens-Uwe Blohmer
Jörg-Olaf Habeck
Kurt Diebold
Marianne Just
Petra Krabisch
P2860
P304
P356
10.1371/JOURNAL.PONE.0079775
P407
P50
P577
2013-12-02T00:00:00Z